Compare CVS Health Corp (CVS) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs D R Horton Inc — how do they compare? CVS Health Corp trades at $86.81 (market cap $112.29B), while D R Horton Inc trades at $134.57 (market cap $37.99B). The key difference: CVS Health Corp is far larger — about 3× D R Horton Inc's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and D R Horton Inc for 46 Days on average.
| CVS | DHI | |
|---|---|---|
Market Cap | $112.29B | $37.99B |
Volume | 7,763,676 | 2,974,460 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $167.78 |
52-Week Low | $70.08 | $132.53 |
Typical Hold Time | 83 Days | 46 Days |
Enterprise Value | $174.64B | $43.09B |
Dividend Yield | 3.03% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
D.R. Horton (DHI) trades at $133.28, down 2.54% on the day amid broader housing sector weakness. The stock shows bearish technical signals with oversold RSI conditions, while fundamentals remain solid with consistent earnings beats and attractive valuation multiples. Recent news highlights pressure from rising mortgage rates and housing market concerns, though the company maintains strong operational cash flow and analyst support.
DHI presents a value opportunity with below-market P/E of 12.95 and 47% analyst buy ratings, but faces headwinds from potential 9% mortgage rates and declining home sales. The consensus price target of $156.57 offers 17% upside, though investors should monitor Q3 2026 earnings on October 29 for margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
